Trial Profile
The prospective, open-lable, single-arm, single-center clinical study for Anlotinib combined with AI in first-line treating patients with recurrent/metastatic soft tissue sarcoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 31 Oct 2018
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary)
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- 31 Oct 2018 New trial record